Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Bio-Rad Laboratories Analyst Ratings
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
Bio-Rad Laboratories Analyst Ratings
UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $385
RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420
Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365
Analysts Are Bullish on These Healthcare Stocks: Bio-Rad Laboratories (BIO), Caribou Biosciences (CRBU)
Bio-Rad Laboratories (BIO) Receives a Buy From RBC Capital
RBC Capital Adjusts Price Target on Bio-Rad Laboratories to $420 From $474
RBC Capital Reaffirms Their Buy Rating on Bio-Rad Laboratories (BIO)
RBC Trims Price Target on Bio-Rad Laboratories to $474 From $480, Keeps Outperform Rating
Bio-Rad Laboratories Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Bio-Rad Laboratories (BIO)
Bio-Rad Laboratories Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Ultragenyx Pharmaceutical (RARE) and West Pharmaceutical Services (WST)
RBC Trims Price Target on Bio-Rad Laboratories to $480 From $484, Keeps Outperform Rating
Bio-Rad Laboratories (BIO) Receives a Buy From RBC Capital
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Bio-Rad Laboratories (BIO)